3397.0 FDA Regulation of Tobacco Products: What it Means for Policy, Practice and Research

Monday, November 9, 2009: 4:30 PM
Session Abstract: Congress approved landmark legislation and President Barack Obama signed it on June 22, 2009 giving the U.S. Food and Drug Administration (FDA) comprehensive authority to regulate the manufacturing, sale, marketing and distribution of tobacco products in the United States. This legislation was the culmination of extensive efforts from a broad range of tobacco control, public health and scientific organizations over more than a decade and is one of the most significant events in tobacco control history. The law provides unprecedented authority to this federal health agency to regulate tobacco products in numerous ways that have previously been unavailable; the lack of previous regulatory authority resulted in numerous deceptions by tobacco companies including the fraud of “light” cigarettes being marketed as less harmful than other cigarettes. This law provides specific power to the U.S. government to reduce the tremendous toll of death and disease caused by tobacco products. This session will: 1) address the history of efforts to regulate tobacco products in the U.S., 2) provide unique insights into the complex legislative process that ultimately produced the law, 3) provide details regarding key legal issues pertaining to implementing the law, 4) share creative ways that states and communities can participate in the regulatory process and discuss examples of new opportunities resulting from the law, and 5) consider key research questions that should be studied to inform the regulatory process. A Senior Official from FDA will be invited to participate and discuss their plans to implement this comprehensive new tobacco control law.
Session Objectives: To provide a better understanding of this new law to regulate tobacco products, some of the key issues involved in passing the legislation, new opportunities for tobacco control efforts at many levels and by many new organizations, and consider crucial unanswered research questions. In addition, participants will learn current plans by FDA staff to implement this landmark legislation, how they might participate in the process and what lessons can be learned to inform efforts to adopt and enact important legislation on other complicated public health topics.
Mitch Zeller, JD , Robin Appleberry, JD, LLM , D. Douglas Blanke, JD, NGS , Lawrence Deyton, MSPH, MD , Karla S. Sneegas, MPH and K. Michael Cummings, PhD MPH

5:20 PM
“Research Priorities Relevant to FDA Legislation to Regulate Tobacco Products”
K. Michael Cummings, PhD MPH, Cathy L. Backinger, PhD, MPH, Dorothy K. Hatsukami, PhD, Scott Leischow and Mitch Zeller, JD

See individual abstracts for presenting author's disclosure statement and author's information.

Organized by: Alcohol, Tobacco, and Other Drugs
Endorsed by: Social Work

CE Credits: Medical (CME), Health Education (CHES), Nursing (CNE), Public Health (CPH)